Elicio Therapeutics (ELTX) Return on Sales (2020 - 2023)

Elicio Therapeutics (ELTX) has 4 years of Return on Sales data on file, last reported at 0.43% in Q1 2023.

• For the quarter ending Q1 2023, Return on Sales fell 35.0% year-over-year to 0.43%; the trailing twelve-month figure through Mar 2023 stood at 0.43% (down 42.0% YoY), and the FY2022 full-year result was 0.12%, down 10.0% from the prior year.
• Return on Sales for Q1 2023 stood at 0.43%, down from 0.15% in the prior quarter.
• Across five years, Return on Sales topped out at 0.06% in Q4 2020 and bottomed at 0.54% in Q1 2021.
• The 4-year median for Return on Sales is 0.13% (2020), against an average of 0.17%.
• The widest annual swing landed in 2022, when Return on Sales jumped 45 bps; it then sank 35 bps in 2023.
• A 4-year view of Return on Sales shows it stood at 0.06% in 2020, then plunged by 91 bps to 0.01% in 2021, then tumbled by 2684 bps to 0.15% in 2022, then sank by 188 bps to 0.43% in 2023.
• The last three Return on Sales figures came in at 0.43% (Q1 2023), 0.15% (Q4 2022), and 0.01% (Q3 2022), per Business Quant data.

Peer Comparison